ClinicalTrials.gg
RecruitingNCT06663917Updated Jun 26, 2026

Clinical Evaluation of Frequency Allocation for Bimodal CI Users

An interventional study of Experimental frequency allocation table (FAT) - 438 Hz and Standard FAT - 188 Hz in Hearing Impairment, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hearing Loss by NYU Langone Health — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss · NYU Langone Health.

Planned enrollment
6th of 10
13 · median 14
Started
2024
the only one that year
No phase
10 of 10
6 open now
Registered
8th of 10
by date

Among the 10 studies in Hearing Loss by NYU Langone Health, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is one of 10 with no phase, and was the 8th registered.

Hearing Loss

797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

6 of the 10 studies in Hearing Loss by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hearing Loss by NYU Langone Health, or all of them as a file.
02

Study summary

This study will examine experienced, bimodal cochlear implant (CI) patients who receive an alternative frequency allocation table (FAT) to determine how it improves sound quality, device satisfaction, and speech perception abilities with respect to the standard default FAT. The goal of this study is to investigate how improving place-pitch mismatch in bimodal CI users affects 1) sound quality, 2) satisfaction, and 3) speech perception.

03

Conditions studied

  • Hearing Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 or older
  2. Regular usage of a cochlear implant device with at least 18 active electrodes, and compliance with programming/appointments
  3. Received a cochlear implant at least 6 months ago and use a hearing aid in the contralateral ear
  4. Pure tone average (.5, 1, and 2kHz) between 30 and 70 dB (decibel) hearing level in the contralateral (hearing aid) ear
  5. Standard FAT use for all programs prior to study participation
  6. No known anatomical abnormalities in either ear
  7. English speaking
  8. No known cognitive impairments
  9. At least 25% of subjects should use the Cochlear EA32 electrode

Exclusion criteria

Exclusion Criteria:

  1. Under age 18
  2. Non-English speaking. Participants that are Non-English speaking are excluded from this study due to the use of speech testing materials that are validated in the English language. Additionally, study team members are not equipped to appropriately score speech testing materials validated in other languages.
  3. Cognitively impaired
  4. Non-consistent device usage
  5. Greater than 70 dB hearing level pure tone average in the contralateral ear
  6. Normal hearing or mild hearing loss in the contralateral ear
  7. Non-standard FAT programs
  8. Use of any frequency transposition programming in hearing aid.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    Experienced Users

    All subjects will be fit with a modified cochlear implant program ("experimental FAT") that changes which frequencies are presented to the cochlear implant. Subjects will complete a 1 month adaptation to the experimental FAT (438 Hz) and then a one month re-adaptation to the standard FAT (188 Hz). Speech perception tests and questionnaires will be collected before and after each FAT adaptation.

    Other: Experimental frequency allocation table (FAT) - 438 Hz · Other: Standard FAT - 188 Hz

Interventions

  • OtherExperimental frequency allocation table (FAT) - 438 Hz

    The modified cochlear implant program ("experimental FAT") changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month.

  • OtherStandard FAT - 188 Hz

    All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.

06

What researchers measure

Primary outcomes

  1. Sound Quality Questionnaire Score while using standard 188 Hz FAT

    A questionnaire will be given to the subjects to record their subjective thoughts regarding sound quality and satisfaction with both the experiment FAT and the standard FAT. Questionnaires will be administered double blind. Patients evaluate the 16-item questionnaire using a likert-scale (1-strongly disagree to 5-strongly agree). Lower scores indicate decreased sound quality and satisfaction, while higher scores indicate increased sound quality and satisfaction.

    Time frame: Baseline

  2. Sound Quality Questionnaire Score while using experimental 438 Hz FAT

    A questionnaire will be given to the subjects to record their subjective thoughts regarding sound quality and satisfaction with both the experiment FAT and the standard FAT. Questionnaires will be administered double blind. Patients evaluate the 16-item questionnaire using a likert-scale (1-strongly disagree to 5-strongly agree). Lower scores indicate decreased sound quality and satisfaction, while higher scores indicate increased sound quality and satisfaction.

    Time frame: Behavioral Visit 2 (1 month post 438 Hz FAT adaptation)

  3. Sound Quality Questionnaire Score while using standard 188 Hz FAT

    A questionnaire will be given to the subjects to record their subjective thoughts regarding sound quality and satisfaction with both the experiment FAT and the standard FAT. Questionnaires will be administered double blind. Patients evaluate the 16-item questionnaire using a likert-scale (1-strongly disagree to 5-strongly agree). Lower scores indicate decreased sound quality and satisfaction, while higher scores indicate increased sound quality and satisfaction.

    Time frame: Behavioral Visit 3 (1 month post 188 Hz FAT re-adaptation)

  4. The consonant-nucleus-consonant (CNC) word list score while using standard 188 Hz FAT

    CNC word lists are used to evaluate the speech perception abilities of people with hearing impairments and cochlear implant users. A CNC score above 50% postoperatively indicates that a patient can communicate without relying too much on lip reading, sign language, or written communication.

    Time frame: Baseline

  5. CNC word list score while using standard 188 Hz FAT

    CNC word lists are used to evaluate the speech perception abilities of people with hearing impairments and cochlear implant users. A CNC score above 50% postoperatively indicates that a patient can communicate without relying too much on lip reading, sign language, or written communication.

    Time frame: Behavioral Visit 2 (1 month post 438 Hz FAT adaptation)

  6. CNC word list score while using standard 188 Hz FAT

    CNC word lists are used to evaluate the speech perception abilities of people with hearing impairments and cochlear implant users. A CNC score above 50% postoperatively indicates that a patient can communicate without relying too much on lip reading, sign language, or written communication.

    Time frame: Behavioral Visit 3 (1 month post 188 Hz FAT re-adaptation)

  7. CNC word list score while using experimental 438 Hz FAT

    CNC word lists are used to evaluate the speech perception abilities of people with hearing impairments and cochlear implant users. A CNC score above 50% postoperatively indicates that a patient can communicate without relying too much on lip reading, sign language, or written communication.

    Time frame: Baseline

  8. CNC word list score while using experimental 438 Hz FAT

    CNC word lists are used to evaluate the speech perception abilities of people with hearing impairments and cochlear implant users. A CNC score above 50% postoperatively indicates that a patient can communicate without relying too much on lip reading, sign language, or written communication.

    Time frame: Behavioral Visit 2 (1 month post 438 Hz FAT adaptation)

  9. CNC word list score while using experimental 438 Hz FAT

    CNC word lists are used to evaluate the speech perception abilities of people with hearing impairments and cochlear implant users. A CNC score above 50% postoperatively indicates that a patient can communicate without relying too much on lip reading, sign language, or written communication.

    Time frame: Behavioral Visit 3 (1 month post 188 Hz FAT re-adaptation)

  10. Bamford-Kowal-Bench (BKB-SIN) speech-in-noise score using standard 188 Hz FAT

    The BKB-SIN speech-in-noise test measures speech perception in noise by assessing a listener's signal-to-noise ratio (SNR) loss. The test results are presented as the SNR loss, which is the amount the signal-to-noise ratio needs to be increased for the listener to correctly repeat 50% of the sentences. A higher SNR loss indicates more difficulty hearing.

    Time frame: Baseline

  11. Bamford-Kowal-Bench (BKB-SIN) speech-in-noise score using standard 188 Hz FAT

    The BKB-SIN speech-in-noise test measures speech perception in noise by assessing a listener's signal-to-noise ratio (SNR) loss. The test results are presented as the SNR loss, which is the amount the signal-to-noise ratio needs to be increased for the listener to correctly repeat 50% of the sentences. A higher SNR loss indicates more difficulty hearing.

    Time frame: Behavioral Visit 2 (1 month post 438 Hz FAT adaptation)

  12. Bamford-Kowal-Bench (BKB-SIN) speech-in-noise score using standard 188 Hz FAT

    The BKB-SIN speech-in-noise test measures speech perception in noise by assessing a listener's signal-to-noise ratio (SNR) loss. The test results are presented as the SNR loss, which is the amount the signal-to-noise ratio needs to be increased for the listener to correctly repeat 50% of the sentences. A higher SNR loss indicates more difficulty hearing.

    Time frame: Behavioral Visit 3 (1 month post 188 Hz FAT re-adaptation)

  13. Bamford-Kowal-Bench (BKB-SIN) speech-in-noise score using experimental 438 Hz FAT

    The BKB-SIN speech-in-noise test measures speech perception in noise by assessing a listener's signal-to-noise ratio (SNR) loss. The test results are presented as the SNR loss, which is the amount the signal-to-noise ratio needs to be increased for the listener to correctly repeat 50% of the sentences. A higher SNR loss indicates more difficulty hearing.

    Time frame: Baseline

  14. Bamford-Kowal-Bench (BKB-SIN) speech-in-noise score using experimental 438 Hz FAT

    The BKB-SIN speech-in-noise test measures speech perception in noise by assessing a listener's signal-to-noise ratio (SNR) loss. The test results are presented as the SNR loss, which is the amount the signal-to-noise ratio needs to be increased for the listener to correctly repeat 50% of the sentences. A higher SNR loss indicates more difficulty hearing.

    Time frame: Behavioral Visit 2 (1 month post 438 Hz FAT adaptation)

  15. Bamford-Kowal-Bench (BKB-SIN) speech-in-noise score using experimental 438 Hz FAT

    The BKB-SIN speech-in-noise test measures speech perception in noise by assessing a listener's signal-to-noise ratio (SNR) loss. The test results are presented as the SNR loss, which is the amount the signal-to-noise ratio needs to be increased for the listener to correctly repeat 50% of the sentences. A higher SNR loss indicates more difficulty hearing.

    Time frame: Behavioral Visit 3 (1 month post 188 Hz FAT re-adaptation)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Data are available indefinitely in Databrary database (Link to be included when database is created). The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be provided access upon reasonable request. Data are available indefinitely in Databrary database (Link to be included when database is created). To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 36 months is above that.

Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Oct 29, 2024
StartActual
Oct 6, 2024
Primary completionEst.
Oct 6, 2027
CompletionEst.
Oct 6, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06663917
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Oct 29, 2024
Start date
Oct 6, 2024
Primary completion
Oct 6, 2027 (estimated)
Completion
Oct 6, 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

Mario Svirsky, PhD
Contact
Mario.svirsky@nyulangone.org
212-263-7217
Megan Eitel
Contact
Megan.eitel@nyulangone.org
212-263-5271
Mario A. Svirsky, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion